Abstract:Main text Under the auspices of the Protein Analysis Working Group (PAWG) of the Comité Consultatif pour la Quantité de Matière (CCQM) a pilot study, CCQM-P216, was coordinated by the Chinese National Institute of Metrology (NIM), National Research Council of Canada (NRC) and the Bureau International des Poids et Mesures (BIPM). Eleven Metrology Institutes or Designated Institutes and the BIPM participated in the first phase of the pilot study (Part 1). The purpose of this pilot study was to develop measurement capabilities for larger proteins using a recombinant humanized IgG monoclonal antibody against Spike glycoprotein of SARS-CoV-2 (Anti-S IgG mAb) in solution. The first phase of the study was designed to employ established methods that had been previously studies by the CCQM Protein Analysis Working Group, involving the digestion of protein down to the peptide or amino acid level. The global coronavirus pandemic has also led to increased focus on antibody quantitation methods. IgG are among the immunoglobulins produced by the immune system to provide protection against SARS-CoV-2. Anti-SARS-CoV-2 IgG can therefore be detected in samples from affected patients. Antibody tests can show whether a person has been exposed to the SARS-CoV-2, and whether or not they potentially show lasting immunity to the disease. With the constant spread of the virus and the high pressure of re-opening economies, antibody testing plays a critical role in the fight against COVID-19 by helping healthcare professionals to identify individuals who have developed an immune response, either via vaccination or exposure to the virus. Many countries have launched large-scale antibody testing for COVID-19. The development of measurement standards for the antibody detection of SARS-CoV-2 is critically important to deal with the challenges of the COVID-19 pandemic. In this study, the SARS-CoV-2 monoclonal antibody is being used as a model system to build capacity in methods that can be used in antibody quantification. Amino acid reference values with corresponding expanded uncertainty of 36.10 ± 1.55 mg/kg, 38.75 ± 1.45 mg/kg, 18.46 ± 0.78 mg/kg, 16.20 ± 0.67 mg/kg and 30.61 ± 1.30 mg/kg have been established for leucine, valine, phenylalanine, isoleucine and proline, respectively. Agreement between nearly all laboratories was achieved for the amino acid analysis within 2 to 2.5 %, with one participant achieving markedly higher results due to a technical issue found in their procedure; this result was thus excluded from the reference value calculations. The relatively good agreement within a laboratory between different amino acids was not dissimilar to previous results for peptides or small proteins, indicating that factors such as hydrolysis conditions and calibration procedures could be the largest sources of variability. Peptide reference values with corresponding expanded uncertainty of 4.99 ± 0.28 mg/kg and 6.83 ± 0.65 mg/kg have been established for ALPAPIEK and GPSVFPLAPSSK, respectively. Not surprisingly due to prior knowledge from previous studies on peptide quantitation, agreement between laboratories for the peptide-based analysis was slightly poorer at 3 to 5 %, with one laboratory's result excluded for the peptide GPSVFPLAPSSK. Again, this level of agreement was not significantly poorer than that achieved in previous studies with smaller or less complex proteins. To reach the main text of this paper, click on Final Report .

Assessment of A Method to Characterize Antibody Selectivity and Specificity for Use in Immunoprecipitation

Automated high-throughput purification of antibody fragments to facilitate evaluation in functional and kinetic based assays.

A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies

Scaling of an antibody validation procedure enables quantification of antibody performance in major research applications

Epitope-directed monoclonal antibody production using a mixed antigen cocktail facilitates antibody characterization and validation

Optimized Sample Preparation and Data Processing of Data-Independent Acquisition Methods for the Robust Quantification of Trace-Level Host Cell Protein Impurities in Antibody Drug Products

An Assessment of Histone-Modification Antibody Quality

Data-driven evaluation of suitable immunogens for improved antibody selection

Characterization of antibody surface properties and selection of a diverse subset for development of a generic size-exclusion chromatography method

High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics

Systematic benchmarking of mass spectrometry-based antibody sequencing reveals methodological biases

Antibody characterization is critical to enhance reproducibility in biomedical research

Anti-drug Antibody Validation Testing and Reporting Harmonization

Highland games: A benchmarking exercise in predicting biophysical and drug properties of monoclonal antibodies from amino acid sequences

Development of a robust and semi-automated two-step antibody purification process

Progress in the development of immunoanalytical methods incorporating recombinant antibodies to small molecular weight biotoxins

Antibody Watch: Text mining antibody specificity from the literature

Comparison of purification strategies for antibodies used in a broad spectrum host cell protein immunoassay

Co-immunoprecipitations Revisited: an Update on Experimental Concepts and Their Implementation for Sensitive Interactome Investigations of Endogenous Proteins

PAWG Pilot Study on Quantification of SARS-CoV-2 Monoclonal Antibody - Part 1

MIB Guides: Measuring the Immunoreactivity of Radioimmunoconjugates